157 related articles for article (PubMed ID: 27578827)
21. Molecular pathology of well-differentiated thyroid carcinomas.
Sobrinho-Simões M; Preto A; Rocha AS; Castro P; Máximo V; Fonseca E; Soares P
Virchows Arch; 2005 Nov; 447(5):787-93. PubMed ID: 16189702
[TBL] [Abstract][Full Text] [Related]
22. Molecular genetics and diagnosis of thyroid cancer.
Nikiforov YE; Nikiforova MN
Nat Rev Endocrinol; 2011 Aug; 7(10):569-80. PubMed ID: 21878896
[TBL] [Abstract][Full Text] [Related]
23. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
[TBL] [Abstract][Full Text] [Related]
24. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
[TBL] [Abstract][Full Text] [Related]
25.
Camargo Barros-Filho M; Barreto Menezes de Lima L; Bisarro Dos Reis M; Bette Homem de Mello J; Moraes Beltrami C; Lopes Pinto CA; Kowalski LP; Rogatto SR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884810
[TBL] [Abstract][Full Text] [Related]
26. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
Castro P; Rebocho AP; Soares RJ; Magalhães J; Roque L; Trovisco V; Vieira de Castro I; Cardoso-de-Oliveira M; Fonseca E; Soares P; Sobrinho-Simões M
J Clin Endocrinol Metab; 2006 Jan; 91(1):213-20. PubMed ID: 16219715
[TBL] [Abstract][Full Text] [Related]
27. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
28. Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population.
Liu S; Gao A; Zhang B; Zhang Z; Zhao Y; Chen P; Ji M; Hou P; Shi B
Exp Mol Pathol; 2014 Oct; 97(2):292-7. PubMed ID: 25111330
[TBL] [Abstract][Full Text] [Related]
29. TERT Promoter Mutations in Papillary Thyroid Microcarcinomas.
de Biase D; Gandolfi G; Ragazzi M; Eszlinger M; Sancisi V; Gugnoni M; Visani M; Pession A; Casadei G; Durante C; Costante G; Bruno R; Torlontano M; Paschke R; Filetti S; Piana S; Frasoldati A; Tallini G; Ciarrocchi A
Thyroid; 2015 Sep; 25(9):1013-9. PubMed ID: 26148423
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutations and long-term survival in patients with thyroid cancer.
Kim TH; Kim YE; Ahn S; Kim JY; Ki CS; Oh YL; Kim K; Yun JW; Park WY; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
Endocr Relat Cancer; 2016 Oct; 23(10):813-23. PubMed ID: 27528624
[TBL] [Abstract][Full Text] [Related]
31. [Diagnostic molecular biology in solid tumors--thyroid gland].
Faksvåg Haugen DR; Varhaug JE; Akslen LA; Lillehaug JR
Tidsskr Nor Laegeforen; 1998 May; 118(14):2199-203. PubMed ID: 9656818
[TBL] [Abstract][Full Text] [Related]
32. [Clinical value of BRAF V600E in thyroid carcinoma and the effect of telomerase reverse transcriptase promoter mutations].
Zhao C; Jia Z
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2019 Apr; 36(2):338-342. PubMed ID: 31016954
[TBL] [Abstract][Full Text] [Related]
33. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
[TBL] [Abstract][Full Text] [Related]
34. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
35. Genetic alterations landscape in paediatric thyroid tumours and/or differentiated thyroid cancer: Systematic review.
de Sousa MSA; Nunes IN; Christiano YP; Sisdelli L; Cerutti JM
Rev Endocr Metab Disord; 2024 Feb; 25(1):35-51. PubMed ID: 37874477
[TBL] [Abstract][Full Text] [Related]
36. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications.
Kowalik A; Kowalska A; Walczyk A; Chodurska R; Kopczyński J; Chrapek M; Wypiórkiewicz E; Chłopek M; Pięciak L; Gąsior-Perczak D; Pałyga I; Gruszczyński K; Nowak E; Góźdź S
PLoS One; 2017; 12(6):e0179691. PubMed ID: 28636673
[TBL] [Abstract][Full Text] [Related]
38. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome.
Tavares C; Melo M; Cameselle-Teijeiro JM; Soares P; Sobrinho-Simões M
Eur J Endocrinol; 2016 Apr; 174(4):R117-26. PubMed ID: 26510840
[TBL] [Abstract][Full Text] [Related]
39. BRAF mutations in papillary thyroid carcinoma.
Wojciechowska K; Lewinski A
Endocr Regul; 2006 Dec; 40(4):129-38. PubMed ID: 17201587
[TBL] [Abstract][Full Text] [Related]
40. Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer.
Alzahrani AS; Qasem E; Murugan AK; Al-Hindi HN; AlKhafaji D; Almohanna M; Xing M; Alhomaidah D; AlSwailem M
Thyroid; 2016 Feb; 26(2):235-41. PubMed ID: 26711586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
